Sample Trade Alert- JAZZ June 11th Report ($7.75)
Below is a sample Alert sent out to our Partners on June 11th at $7.75 a share. The stock is now $8.55 just a few trading days later:
JAZZ- This is the 3rd time I have recommended this stock in 8 months. First time 60% gain within days, second time we got stopped out for no gain and it ran up 80% later on (Stopped out in early Feb).
3rd time now is at 7.75 with recent heavy insider buy at $8.30 in a new secondary offering at $8.30. The same Director/Insider has bought in the past at major pivot bottoms, and this time he took up $7 million worth of the secondary offering. Insider Buy LINK
WBB Initiates coverage with Buy on May 17th- $15 Target
JAZZ has has two drugs on the market, and they are estimating 60-80 cents in adjusted EPS this year, and 30-40% revenue growth. They have a Fibromyalgia drug pending FDA approval in November, with a panel advisory in late summer early fall. Approval there will push the stock way up. The stock has pulled way back from 14 to 7.75. JAZZ is paying down 1/2 their debt with this offering, and the debt is at 15%.
Further, JAZZ likely to be added to the Russell 2000 index with news tonight due on that, and the date is June 25th. Index funds must have the stock in their portfolio by that closing day.
1/3 position, max $8, but try to buy 7.90 or lower. Stop loss at$7.34 for a 5-6% max downside on a 1/3 initial position:
All of this is explained in this 5 minute video and everyone should watch it. In the video I mention the Hedge fund taking up the entire offering, that is incorrect, they took up $7 million of the offering
